Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

✍ Scribed by Younes, Anas (author);Gopal, Ajay K. (author);Smith, Scott E. (author);Ansell, Stephen M. (author);Rosenblatt, Joseph D. (author);Savage, Kerry J. (author);Ramchandren, Radhakrishnan (author);Bartlett, Nancy L. (author);Cheson, Bruce D. (author);De Vos, Sven (author);Forero-Torres, Andres (author);Moskowitz, Craig H. (author);Connors, Joseph M. (author);Engert, Andreas (author);Larsen, Emily K. (author);Kennedy, Dana A. (author);Sievers, Eric L. (author);Chen, Robert (author)

• Book ID: 118022658
• Publisher: American Society of Clinical Oncology
• Year: 2012
• Tongue: English
• Weight: 173 KB
• Volume: 30
• Category: Article
• ISSN: 0732-183X
• DOI: 10.1200/jco.2011.38.0410